MESO · Mesoblast

The thesis

Mesoblast's approved cell therapy Ryoncil is growing from a year earlier but fell from the previous quarter, so the shares are more likely to lag the S&P 500 over the next three months until sales recover. The quarterly report for the three months to 31 December 2026, due around January 2027, settles whether the September dip was seasonal, as the company says.

Ryoncil net revenue was US$28 million in the quarter ended 30 September 2026, up 44% from a year earlier and down from US$36 million in the June 2026 quarter (Mesoblast activity report, 28 October 2026). The shares closed at $13.10 on 12 November 2026, 39.1% below the 52-week high of $21.50 (intraday, 9 January 2026). They have closed lower in each of the last three sessions, from $14.44 on 9 November 2026.

The company blames the dip on summer-recess treatment scheduling in July and August. It says September had the highest monthly count of new patient starts (activity report as summarized by finviz, 28 October 2026). A December-quarter figure above US$28 million would support that explanation. A second fall would not.

Bullish and bearish views on Mesoblast Limited

The bull case on Mesoblast Limited (MESO), in brief: Ryoncil is growing year on year. The bear case: sales fell from the prior quarter.

Bull case

• Ryoncil is growing year on year. Net revenue of US$28 million in the September 2026 quarter was 44% above the prior-year quarter (activity report, 28 October 2026). Fiscal 2026 Ryoncil net revenue was US$115 million (company results release, 27 August 2026).
• Cash burn is small. Operating cash spend was US$2.1 million in the September quarter against US$14.9 million a year earlier. Cash was US$99 million at 30 September 2026 (activity report, 28 October 2026).
• The adult label trial is enrolling. The company says the registration trial in adults with steroid-refractory acute graft-versus-host disease has started, with up to 40 US sites expected to be active by the end of 2026 (activity report, 28 October 2026).
• The FDA confirmed a filing path for heart-pump bleeding. The company says the FDA confirmed a biologics license application for rexlemestrocel-L may proceed in end-stage heart failure patients with a left ventricular assist device and life-threatening gastrointestinal bleeding. Formal meeting minutes are expected shortly (activity report, 28 October 2026).
• Physicians are promoting first-line pediatric use. Mesoblast hosted a key opinion leader webinar on 5 November 2026 on using Ryoncil first-line after steroids in pediatric acute graft-versus-host disease (company news).

Bear case

• Sales fell from the prior quarter. Net revenue of US$28 million compares with US$36 million in the June 2026 quarter. On the 26 August 2026 call, management guided to double-digit Ryoncil growth over the following 12 months, and the September-quarter report gave no new guidance.
• Debt offsets the cash. Cash of US$99 million sits against a fully drawn US$125 million facility at a fixed 8% rate, interest-only through December 2030 and secured on Ryoncil royalties. Fiscal 2026 net loss was US$57.5 million (results release, 27 August 2026).
• One product and one indication carry sales. Nearly all revenue comes from pediatric steroid-refractory acute graft-versus-host disease. Adult revenue depends on a trial that started in 2026.
• The key trial readout is months away. The 350-patient chronic low back pain Phase 3 trial reads out in 2027 on a 12-month pain-reduction endpoint (activity report, 28 October 2026). The written fiscal 2026 release says mid-2027 and the chief executive said the second half of 2027 on the call.
• Management turnover is rising. Mesoblast announced board rotational changes and retirements on 2 November 2026 and named an interim chief operating officer on 10 November 2026 (company news). The three-month price change was −16.0% as of the 12 November 2026 close.

Price setup

The shares closed at $14.10 on 5 November 2026, $14.27 on 6 November 2026 and $14.44 on 9 November 2026. They then closed at $13.99 on 10 November 2026, $13.65 on 11 November 2026 and $13.10 on 12 November 2026. The 52-week closing low is $11.95, set on 19 October 2026.

The last adjusted close of $13.10 sits below both the 50-day average of closes ($14.4) and the 200-day average of closes ($15.23). The close on 14 August 2026, the three-month reference, was $15.60. The rally of early November faded before it reached the 200-day average.

Crowding is limited. No earnings date falls inside 30 days. Mesoblast is a foreign private issuer, so insider trades appear as ASX Appendix 3Y notices rather than SEC Form 4 filings. Company news through 10 November 2026 shows no equity offering.

Catalysts ahead

• November 2026 (undated): Formal FDA meeting minutes on a biologics license application for rexlemestrocel-L in left-ventricular-assist-device patients with gastrointestinal bleeding. The wording shows how far the FDA has agreed to a modular filing and whether the pipeline widens beyond chronic low back pain.
• ~31 December 2026 (est.): Activation deadline for up to 40 US sites in the adult graft-versus-host disease registration trial. On-schedule activation supports the route to an adult label, the main extension of Ryoncil sales.
• ~January 2027 (est.): Activity report for the December 2026 quarter. Shows whether Ryoncil net revenue recovers above the US$28 million of the September 2026 quarter toward the US$36 million of June 2026, or falls again.
• 2027 (mid to second half): Phase 3 chronic low back pain trial readout. The binary pipeline event; the written release says mid-2027 and the chief executive said the second half of 2027.

What would change the view

A daily close above $15.26, just over the 200-day average of closes, which would show the shares leading the S&P 500. A December 2026 quarter Ryoncil net revenue figure above the US$36 million of June 2026 would also show the shares leading.

What it trades with

Mesoblast trades as a single-asset, event-driven biotech. Its Nasdaq-listed American depositary shares follow the Australian ordinary shares (ASX: MSB), so US moves often follow the prior Australian session. The shares respond mainly to quarterly Ryoncil revenue, FDA communications and funding news. Their link to broad technology or index moves is weak, and no figure in this note measures it.